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Abstract 48 
Background: Heart failure with preserved ejection fraction (HFpEF) is under-identified in primary 49 
care. 50 
Aim: The aim of this study was to determine what information is available in patients’ primary care 51 
practice records that would identify patients with HFpEF. 52 
Design and Setting: Record review in two practices in East of England. 53 
Methods: Practices completed a case report form on each patient on the heart failure register and 54 
sent anonymised echocardiography reports on patients with an ejection fraction (EF) > 50%. Reports 55 
were reviewed and data analysed using SPSS. 56 
Results: 148 patients on the HF Registers with mean age 77 + 12 years were reviewed.  Fifty-three 57 
patients (36%) had possible HFpEF based on available information.  These patients were older and 58 
multi-morbid, including high prevalence of overweight and obesity. Confirmation of diagnosis was 59 
not possible as recommended HFpEF diagnostic information (natriuretic peptides, echocardiogram 60 
parameters of structural heart disease and diastolic function) was widely inconsistent or absent in 61 
these patients.   62 
Conclusion: Without correct identification of HFpEF, patient management may be sub-optimal or 63 
inappropriate, and lack the needed focus on comorbidities and lifestyle that can improve patient 64 
outcomes. We have described in detail the characteristics of many of the patients who probably 65 
have HFpEF in a real-world sample, and the improvements and diagnostic information required to 66 
better identify them. Identifying more than the tip of the iceberg that is the HFpEF population will 67 
allow us to improve the quality of their management, prevent ineffective healthcare and recruit 68 
patients into research.   69 
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The Tip of the Iceberg: Finding Patients with Heart Failure with Preserved Ejection Fraction in 81 
Primary Care 82 
Introduction  83 
Heart failure affects 900,000 people in the UK and accounts for 2% of NHS expenditure, primarily 84 
due to emergency hospitalisations (1, 2).    Many clinicians in general practice may be surprised to 85 
know that approximately half of these patients have a type of heart failure called HFpEF (heart 86 
failure with a preserved ejection fraction), as very few of these patients ever receive a specific 87 
diagnosis.(3-7). This really matters, as HFpEF patients need a different management strategy to 88 
patients with heart failure with reduced ejection fraction (HFrEF, where the heart ejects less than 89 
40% of its volume of blood each time it contracts). Patients with HFpEF need a focus on regulation of 90 
fluid status with diuretics, self-management including diet and exercise, and control of comorbid 91 
conditions such as atrial fibrillation (AF) and hypertension, rather than drugs and devices which are 92 
the main stay for HFrEF(8, 9).  Misdiagnosis also undermines quality improvement and research into 93 
HFpEF.  Misdiagnosis would no longer be tolerated in fields such as diabetes and stroke, where 94 
specific diagnosis is understood to be vital for patient care, and should no longer be tolerated in the 95 
field of heart failure. 96 
However, diagnosing HF without a reduced left ventricular ejection fraction (LVEF) is more complex 97 
and this complexity likely stems from an incomplete understanding of the exact pathophysiological 98 
processes leading to HFpEF, changes in and lack of agreement on diagnostic criteria, a 99 
heterogeneous population with HFpEF, a lack of specific evidence-based treatment, and a focus on 100 
HFrEF for whom evidence-based treatment exists (5, 8, 10-14). The recent ESC guidelines on acute 101 
and chronic heart failure (8) define HFpEF as symptoms and signs of HF, an LVEF > 50%, elevated 102 
levels of natriuretic peptides and at least one additional criterion: i) relevant structural heart disease 103 
(left ventricular hypertrophy and/or left atrial enlargement; ii) diastolic dysfunction (Box 1).  These 104 
criteria pose some challenges for primary care practitioners. Although recommended to rule out HF 105 
by the ESC and NICE, not all patients presenting with suspected HF in primary care have natriuretic 106 
peptides measured.  Left ventricular hypertrophy (LVH) and left atrial enlargement are easily and 107 
frequently assessed but other recommended echocardiographic parameters for HFpEF are more 108 
technically challenging and require specialist interpretation.  Diastolic dysfunction is defined by 109 
specific indices on echocardiogram measuring mitral valve early and late diastolic inflow, early 110 
diastolic tissue velocity, the ratio between early mitral inflow velocity and mitral annular early 111 
diastolic velocity and peak tricuspid regurgitation velocity (8, 15).  Although not a diagnostic 112 
parameter, elevated pulmonary artery systolic pressure is common, and is an important indicator for 113 
prognosis and management. Recommendations for what to measure on echocardiogram and values 114 
considered abnormal differ between professional groups (Box 2).   115 
Primary care provides sole or shared care for all patients with heart failure in the UK, and maintains 116 
registers of heart failure patients as mandated by the Quality Outcomes Framework(QOF). QOF also 117 
requires that an echocardiogram is done to confirm or refute the HF diagnosis.  The aim of this study 118 
was to determine what information was available in patients’ full primary care practice records to 119 
identify patients with heart failure with preserved ejection fraction from within practice heart failure 120 
patient registers. 121 
Methods  122 
Two primary care practices in the East of England were recruited for the study; one urban and one in 123 
a smaller town accessing echocardiography services run by different hospitals.  Each practice 124 
completed a simple case report form (CRF) on each patient on the heart failure register of the 125 
practice requesting brief demographic and clinical information.  Data were collected during 2016-17, 126 
but included patients on HF registers regardless of when diagnosed. Practices were asked to send 127 
anonymised echocardiography reports on all patients with an ejection fraction > 50%, or those 128 
patients with LVEF labelled as ‘normal, preserved or near-normal’.  The echocardiography reports or 129 
letters detailing echocardiographic information were scrutinised for parameters measured and 130 
assessment of left ventricular diastolic function.  131 
Data were entered into an SPSS database by the research nurse and re-checked by the principle 132 
investigator (PI).  The PI and a consultant cardiologist reviewed the data and echocardiographic 133 
reports and letters on each patient.  Patients were divided into three groups based on ejection 134 
fraction as defined by the ESC (8): EF < 40% (HFrEF or LVSD), EF 40 – 49% as heart failure with a mid-135 
range EF (HFmrEF), and EF > 50% (HFpEF).  Patients were included in the HFrEF category if their 136 
systolic function was described as severely impaired even if a numeric value was not provided.  137 
Similarly patients were included in the HFpEF category if their EF was described as normal, near-138 
normal or preserved.  A fourth group comprised those patients for whom echocardiographic data 139 
were missing or not clear enough for categorisation. This final group included those with 140 
descriptions of mild, moderate or mild-moderate systolic dysfunction as there was uncertainty 141 
regarding matching these descriptors to a specific numerical LVEF.   These groups were compared on 142 
demographic and clinical characteristics.   143 
Results   144 
The two practices participating in this study differed in size and socioeconomic deprivation of the 145 
practice area.  The urban practice had a list size of 7890, with 48 patients on the HF register, and was 146 
in the least deprived decile for socioeconomic status.  The town practice had a list size of 13,229 147 
with 100 patients on the HF register, and was in the fifth most deprived decile. The proportion of 148 
patients aged 65 and older were similar (15-17%) and both practices had predominantly white 149 
patients. Non-white ethnicity ranged from 5% (in the smaller town practice) to 19% (urban).    150 
CRFs were completed on 148 patients aged 40 – 99 years. Patients had a mean age 77 + 12 years 151 
with multiple comorbid conditions and a high prevalence of overweight and obesity (Table 1).  152 
Echocardiogram reports or letters were unavailable or did not provide enough information to 153 
characterise 31 patients (21%) by ejection fraction.  This 21% included patients placed on the HF 154 
register prior to the Quality Outcomes Framework requirement for echocardiographic confirmation 155 
of HF, patients awaiting echocardiography,  echocardiograms reported as technically difficult with 156 
limited data, and a few with unknown reasons for lack of echocardiogram reports. Sixty-nine of the 157 
patients (56% of those with an echocardiogram) had a numeric ejection fraction provided, and the 158 
other reports used verbal descriptions (e.g. preserved, or moderately impaired) to describe systolic 159 
function and ejection fraction. 160 
Grouping patients by ejection fraction resulted in 43 patients (29%) with EF < 40% or labelled severe 161 
systolic dysfunction or severely impaired EF, 21 (14%) with EF 40 – 49%, 53 (36%) with EF > 50% or 162 
described as having normal, near-normal or preserved EF, and 31 (21%) missing or unable to be 163 
categorised.  Small sample sizes in the groups precluded finding significant differences in 164 
characteristics by EF group except for a lower recorded prevalence of atrial fibrillation in patients for 165 
whom echocardiographic data were missing or unclear (Table 2).  Patients with EF > 50% had a mean 166 
age of nearly 80, 83% had hypertension, 81% were overweight or obese, 65% had more than 3 167 
comorbid conditions, half had chronic kidney disease (CKD), 45% were women, and nearly a third 168 
had diabetes. Although not significant, there were trends toward older age, higher proportion of 169 
women, greater prevalence of obesity and multiple comorbidities, and lower rates of ischaemic 170 
heart disease in patients with EF > 50% compared to those with EF < 40%.  Only 9% of the total 171 
sample had natriuretic peptides (NT-ProBNP) results available in the record. Six of the 53 patients 172 
with an EF > 50% had natriutric peptides measured, with 5 of these being elevated well above the 173 
ESC guideline recommended level for considering a diagnosis of HF (NT-ProBNP > 125 pg/mL)(8).   174 
Seven of the 43 patients with EF < 40% had NT-ProBNP results.  The mean NT-ProBNP for those with 175 
EF > 50% was 2699 + 2138 pg/mL compared to 4858 + 6479 pg/mL for those with EF < 40%. 176 
Echocardiographic Data: For the 53 patients with documented EF > 50% we found that 39 had 177 
echocardiographic reports that included at least one of the parameters recommended for 178 
diagnosing HFpEF and diastolic dysfunction (Table 3).  Left ventricular size and mass were 179 
commented on in 35 and left atrial size and volume were discussed in 33.  Sixteen of 35 patients 180 
(46%) had at least some degree of left ventricular hypertrophy (LVH), and the left atrium was dilated 181 
in 28 of 33 patients (85%).  Only in seven of the 39 patients (18%) were both the left atrium and left 182 
ventricle normal. At least one measure of diastolic function was available in 24 patients and 17 had 183 
at least one abnormal measure.  Comments about diastolic function were found in reports of 12 184 
patients, with 11 of these patients having some degree of diastolic dysfunction noted, and one with 185 
elevated filling pressures.  However measurements of specific indices of diastolic function were not 186 
documented in five patients with diastolic dysfunction noted on the report.   187 
In total 24 patients had both measures of relevant structural heart disease and diastolic function, 188 
and 15 patients had abnormal values of both of these.   Seven patients had pulmonary hypertension 189 
(PH) or possible PH documented, and pulmonary artery systolic pressures were available in 9 190 
patients.   Differences on echocardiogram reports in measurements and information provided for 191 
patients with possible HFpEF differed by individual echocardiographers, more so than the service.  192 
This finding was independent of reports of technical or other difficulties in performing the 193 
echocardiogram. 194 
Diagnosis 195 
Very few patients would have met the ESC diagnostic criteria for HFpEF given the lack of 196 
recommended measurements.  Although 73.5% of the 53 patients with possible HFpEF had at least 197 
one measure of structural heart disease and/or diastolic function assessed, there was a lack of 198 
consistency in which indices were measured and how many were reported. Natriuretic peptide 199 
levels were available in less than 10% of all of the patients. 200 
Discussion -  201 
Summary  In two Primary Care registers of heart failure patients, our study found that patients with 202 
possible HFpEF comprised 36% of the patients. This group of patients were on average a few years 203 
older than the other HF patient groups, and had a high comorbidity burden including the highest 204 
prevalence of being overweight or obese. Confirmation of diagnosis was not possible as precise 205 
HFpEF diagnostic information was widely inconsistent or absent in these patients.  206 
Echocardiographic indices related to diastolic function (and to a less extent structural heart disease), 207 
and interpretation of findings related to HFpEF were extremely limited or missing. An additional 21% 208 
of patients had missing echocardiograms or were unable to be categorised by ejection fraction, and 209 
this may include additional patients with HFpEF.  Natriuretic peptide results were also infrequently 210 
available.  211 
Strengths and limitations: The strength of the study was in the thorough review of anonymised 212 
echocardiographic reports and case report forms from patients on the HF registers of two primary 213 
care practices in different areas, and comparison with recommended criteria for diagnosing HFpEF.  214 
However we did not include a search for patients with HF who may not have been on the HF 215 
registers.  HF registers have been found to have varying levels of accuracy (16) , and patients may be 216 
placed on the HF Register prior to confirmation. A further limitation of the study is that there were a 217 
limited number of patients and both practices were in the East of England with limited ethnic 218 
diversity.   219 
Comparison with existing literature:  220 
Patients with HFpEF comprise half of the patients with HF, and epidemiological analyses have shown 221 
an increasing prevalence of patients with HFpEF especially among those referred to acute services 222 
from the community (17).  Given the mean age of the patients on the two HF Registers (77 years) in 223 
this study, a higher proportion of patients with possible HFpEF would be expected. A pooled analysis 224 
of 105 studies with 196,105 patients with undifferentiated HF recruited from general practice 225 
indicated that the predominant phenotype was an older woman with hypertension rather than 226 
ischaemic heart disease (18), which would be suggestive of a high prevalence of HFpEF. The patients 227 
with possible HFpEF in the current analysis had a non-significant trend toward older age, higher 228 
proportion of women and multiple comorbidities. The increasing prevalence of HFpEF among older 229 
patients suggests that we are only identifying the tip of a potential iceberg of patients with HFpEF in 230 
primary care.    231 
Both under-diagnosis and over-diagnosis of HF in primary care have been found in other studies (6, 232 
19, 20).  Various routes to diagnosis of HF in patients in UK primary care have been documented, 233 
with nearly 80% of patients being diagnosed in secondary care, and less than one quarter following 234 
the recommended NICE diagnostic pathway (21).   A recent survey found that most GPs (84%) did 235 
not diagnose HFpEF, and only 7% were very confident in their ability to do so(22). Although 236 
echocardiography is an essential tool for determining the diagnosis and type of HF it has been found 237 
to be under-used in general practice.  In a study of 683 patients in 30 general practices with a HF 238 
diagnosis, only 45.2% had undergone an echocardiogram at the start of the study 2010-11 (19).  239 
Munoz and colleagues (23) analysed records from 8376 patients with diagnoses of HF in 52 primary 240 
care practices in Barcelona 2009 - 2012.  The majority of patients (91.5%) did not have an available 241 
EF.  Most of the patients in our analysis had an echocardiogram done, which may be due to the 242 
influence of the QOF criteria.  However many GPs in the UK lack confidence in interpretation of 243 
echocardiography reports from open access services, especially in regards to HFpEF (22). 244 
Although echocardiogram reports or letters describing results were available for the majority of 245 
patients in our study, data on echocardiographic indices to diagnose HFpEF were inconsistently and 246 
infrequently measured in patients with possible HFpEF.   Guidelines such as the ESC specify what 247 
needs to be measured for HFpEF assessment, but disagreement regarding criteria exists.  The ESC 248 
guidelines (8) do not specify how many measures of diastolic function need to be abnormal to 249 
establish a diagnosis of diastolic dysfunction, but the American Society of Echocardiography and the 250 
European Association of Cardiovascular Imaging (15) require at least half of 5 recommended 251 
parameters to be abnormal. The British Society of Echocardiography (BSE) minimum dataset includes 252 
a few parameters related to diastolic function, and they have also published a practical guide on 253 
assessment and grading of diastolic dysfunction.  The BSE noted that confidence in assessing and 254 
grading diastolic dysfunction increases with increasing numbers of corroborative parameters but 255 
does not specify how many (24, 25). The inconsistency in reports seen in this analysis could also 256 
reflect local/regional practice and guidance, limited time for echo appointments in busy services, 257 
and limited patient information provided in referral.  The inconsistency in reporting specific 258 
parameters varied by echocardiographers within the two services rather than by service. 259 
Other important characteristics and prognostic indicators such as pulmonary artery pressures were 260 
also infrequently documented in this sample of patients.  In a community sample of 244 patients 261 
with HFpEF, elevated pulmonary artery systolic pressures were found in 83% of patients (26), and 262 
higher PASP was associated with mortality (age-adjusted HR 1.22 per 10 mm Hg, p < .005).  Another 263 
analysis (1663 patients with HF) found an elevated PASP > 40 mm Hg to be an independent predictor 264 
of survival in patients with HF and an EF > 40% with a hazard ratio of 2.27 (95% CI 1.58 – 3.26, p < 265 
0.001)(27).  266 
Implications for practice: The lack of consistent and relevant information and interpretation of 267 
findings from echocardiography and other diagnostic tests for patients with suspected HF could lead 268 
to misdiagnosis and inappropriate treatment. Patients with HFpEF may have reason to be on similar 269 
medications to those with HFrEF for control of hypertension and other cardiac conditions, but these 270 
should not be prescribed automatically as HFpEF-specific treatment due to lack of efficacy in 271 
improving mortality and morbidity.  Some health care professionals may argue that until there are 272 
evidence-based treatments for management of HFpEF, a formal diagnosis of HFpEF is unnecessary.  273 
However there is a clear message that HFrEF and HFpEF are not the same, that clinicians must treat 274 
HFpEF now by managing comorbidities, and that the greatest reductions in mortality and morbidity 275 
may result from treating comorbidities (9, 14).  In the CHARM clinical trial with over 1000 patients 276 
with HFpEF, the burden of non-cardiac conditions accounted for a greater proportion of risk for 277 
death than cardiac burden (population attributable risk 49% v 15%, p < 0.05) (28).  Comorbid 278 
conditions have a greater impact on functional class and physical health status in HFpEF, and 279 
hospitalisations and readmissions for non-cardiac causes are higher in patients with HFpEF 280 
compared to HFrEF (29, 30).  An analysis of over 43,000 patients hospitalised for HFpEF in the US 281 
found a 1 year composite of mortality and all-cause readmission to be 74% (31).   282 
Patients with HFpEF will also benefit from a focus on self-management and lifestyle factors.  Physical 283 
activity has been shown to improve fitness and quality of life in patients with HFpEF(32), and 284 
emerging evidence indicates that weight loss may also improve outcomes in obese patients (33). 285 
Patients experiencing problems with fluid overload may benefit from restrictions in fluid and salt 286 
intake.  Diet non-compliance was shown to be a precipitating factor in hospitalisation for HF 287 
regardless of LVEF, and in another analysis patients with HFpEF who received sodium-restriction 288 
dietary instruction at time of hospital discharge had significantly lower risk of 30-day combined 289 
readmission and death (34, 35).   290 
Conclusions 291 
The findings of this paper have highlighted that there is a deficit in identification of patients with 292 
HFpEF.  The implications for this are that without correct identification patient management may be 293 
sub-optimal or inappropriate, and lack the needed focus on comorbidities and lifestyle that can 294 
improve patient outcomes. Furthermore, without correct identification patients cannot be recruited 295 
into clinical trials and other studies that could develop and test HFpEF specific therapies. We have 296 
described in detail the characteristics of many of the patients who probably have HFpEF in a real-297 
world sample, and the improvements and diagnostic information (comprehensive echocardiogram 298 
reports and natriuretic peptides) required to better identify them. Identifying more than the tip of 299 
the iceberg that is the HFpEF population will allow us to improve the quality of their management, 300 
prevent ineffective healthcare and recruit patients into research.   301 
 302 
How this fits in 303 
• Patients with HFpEF comprise half of the patients with HF but are under-identified in 304 
primary care. 305 
• Patients with possible HFpEF seldom had natriuretic peptides measured, and lacked 306 
consistent echocardiographic measurement of relevant parameters for structural heart 307 
disease and diastolic function needed for diagnosis. 308 
• The absence of relevant diagnostic information and interpretation in primary care hinders 309 
identification and appropriate management of patients with HFpEF. 310 
 311 
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Iceberg Tables 
Table 1: Characteristics of Sample 
 Patients on Heart Failure Registers (n = 148) 
Age 76.9 + 12 years 
Duration of HF diagnosis 5.3 + 4 years 
Female Sex 38.5% 
Hypertension 84% 
Chronic kidney disease 44%
Atrial fibrillation 41% 
BMI 25 – 29.9 kg/m2 
BMI > 30 kg/m2 
31% 
39% 
Ischaemic heart disease 32% 
Diabetes 25%
Valvular heart disease 22% 
COPD 16% 
Stroke 15% 
Asthma  10%
Current smoker 
Ex-smoker 
10% 
30% 
Echocardiogram information available 79% 
COPD = chronic obstructive pulmonary disease, HF = heart failure; kg/m2  = kilograms per metre squared 
  
 Table 2: Clinical Characteristics by EF Group  
Characteristics EF < 40%  
(n = 43) 
 
EF 40 – 49% 
(n = 21) 
 
EF > 50%  
(n = 53) 
Unclear or 
missing  
(n = 31) 
P value 
Mean Age (sd) 76 (13) 76 (13) 79.8 (11) 74.2 (11) 0.161 
Female Sex 30% 29% 45% 46% 0.293 
Hypertension 80% 81% 83% 93% 0.442
IHD 39% 29% 30% 29% 0.743 
CKD 39% 38% 51% 42% 0.615 
Diabetes 24% 9.5% 32% 26% 0.254 
AF 49% 43% 47% 19% 0.048
COPD 12.2% 9.5% 19% 19.4% 0.638 
Stroke 15% 14% 17%  13% 0.964 
Valvular HD 24% 24% 28% 6.5%  0.123
BMI 25 – 29.9 kg/m2   33% 18% 34% 30% 0.630 
BMI > 30 kg/m2   33% 29% 47% 40% 0.503 
> 3 comorbidities 51% 41% 65% 63% 0.270 
Mean Duration HF (sd) - 
years 
4.3 (4.5) 5.9 (4.4) 5 (3.99) 6.9 (5) 0.088
AF = atrial fibrillation; BMI = body mass index; CKD = chronic kidney disease; COPD = chronic obstructive 
pulmonary disease, HF = heart failure; IHD = ischaemic heart disease; kg/m2  = kilograms per metre squared;  
sd = standard deviation 
 
  
 Table 3. Echocardiographic Data in 39 Patients with EF > 50%  
 EF > 50%* 
 
Mean EF (sd) 57 + 5% 
At least one recommended measure of structural heart disease documented
           LVH present 
                     Concentric LVH 
           LA dilated 
           Both LV and LA normal  
35/39 (89.7%)
16/35 (46%) 
6/16 (37.5%) 
28/33 (85%) 
7/39 (18%) 
At least one recommended index of diastolic function measured 
• E/A ratio  
• e’ lateral  
• e’ septal  
• E/e’ mean  
• TRV  
24/39 (61.5%) 
13 
5 
5 
19 
14 
At least one recommended index of diastolic function is abnormal 
Number of diastolic function indices that are abnormal 
• One 
• Two 
• Three  
• Four 
17/24 (71%) 
 
8 
5 
3 
1 
Diastolic dysfunction labelled on report or in letter where diastolic function 
mentioned 
11/20 (55%)  
RV dysfunction present 7/31 (22%) 
RV dilation 9/27 (33%) 
PH documented  7/26 (27%) 
* includes patients labelled as having a ‘normal’, ‘near-normal’ or ‘preserved’ EF 
EF = ejection fraction; e’ = early diastolic tissue velocity; E/e’ = ratio between early mitral inflow 
velocity and mitral annular early diastolic velocity; LA = left atrium; LVH = left ventricular 
hypertrophy; PH = pulmonary hypertension; RV = right ventricle; TRV = peak tricuspid regurgitation 
velocity  
 
  
Box 1 Diagnosis of Heart Failure with Preserved Ejection Fraction (3) 
Signs and symptoms of heart failure 
Ejection fraction > 50% 
Elevated natriuretic peptides (BNP > 35 pg/mL or NT-ProBNP > 125 pg/mL) 
At least one additional criterion: 
a) relevant structural heart disease (LVH and/or LAE) 
b) diastolic dysfunction 
BNP = brain natriuretic peptide; LAE = left atrial enlargement; LVH = left ventricular hypertrophy; 
pg/mL = picograms per millilitre   
Box 2 Recommended echocardiographic indices for diagnosing HFpEF and diastolic dysfunction 
European Society of Cardiology Clinical Practice Guidelines on Acute and Chronic Heart Failure 
2016 (3) 
Relevant structural heart disease 
• Left ventricular hypertrophy (left ventricular mass index > 115 g/m2 for males and > 95 g/ m2 
for females) 
• Left atrial enlargement (left atrial volume index > 34 mL/ m2)  
Diastolic dysfunction 
• Early diastolic tissue velocity (e’ mean septal-lateral < 9 cm/s) 
• Ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e’> 
13)  
• Deceleration time (DecT) of mitral valve early diastolic inflow (MV-E) m/s  
• E/A ratio < 1 or > 2 
• Isovolumetric relaxation time (IVRT) 
American Society of Echocardiography and the European Association of Cardiovascular Imaging 
2016 (9) 
Annular e’ velocity  
• Septal e’ < 7 cm/sec 
• Lateral e’ < 10 cm/sec  
Average E/e’ ratio > 14 
Left atrium maximum volume index (> 34 mL/ m2) 
Peak tricuspid regurgitation velocity > 2.8 m/sec 
 
Note: LV diastolic function is normal if more than half of the variables do not meet the cut-off for 
identifying abnormal function.  
cm/sec = centimetres per second; DecT = deceleration time; E= early mitral diastolic inflow; e’ = 
early diastolic tissue velocity; E/e’ = ratio between early mitral inflow velocity and mitral annular 
early diastolic velocity; g/ m2 = grams per metre squared; LV = left ventricle; m/s = metres per 
second; mL/ m2 = millilitres per metre squared; MV = mitral valve; 
 
 
 
 
 
 
 
 
